Shalby Limited Q1 FY27 Financials

Standalone Revenue: ₹253.79 crore
Consolidated Revenue: ₹331.22 crore

Reader Takeaway: Healthcare services drive profit; implant segment losses persist, impacting overall results.

What just happened

Shalby Limited announced its financial results for the quarter ending June 30, 2026. The company reported standalone revenue of ₹253.79 crore and consolidated revenue of ₹331.22 crore for the period. Consolidated profit after tax for the quarter stood at ₹10.50 crore.

Why this matters

The results reveal a mixed performance across its business segments. The core Healthcare Services segment demonstrated strong profitability with revenue of ₹288.81 crore and a profit of ₹31.18 crore. This highlights the strength and resilience of its hospital operations.

However, the Manufacturing & Trading of Implants segment continued to face challenges, reporting a loss of ₹11.48 crore on revenues of ₹42.41 crore. This segment's performance is a key concern for investors.

The backstory

Shalby Limited is a multi-specialty hospital group with a significant presence in orthopaedics. It also operates a manufacturing division for orthopaedic implants and surgical and medical devices.

What changes now

The company has made key leadership and structural changes. Mr. Shanay Vikram Shah has been appointed as an Additional Director and Whole-Time Director for five years, pending shareholder approval. Additionally, its wholly-owned subsidiary, Shalby Medtech Limited, has acquired the remaining stake in Shalby Global Technologies Pte. Ltd., making it a fully owned entity. PricewaterhouseCoopers Services LLP has been appointed as Internal Auditors for FY 2026-27.

Risks to watch

The primary risk remains the sustained losses in the Manufacturing & Trading of Implants segment. Investors will be watching for strategies to improve operational efficiency and profitability in this division.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

Consolidated Profit for the Period (Q1 FY27): ₹10.50 crore
Healthcare Services Segment Profit (Q1 FY27): ₹31.18 crore
Manufacturing & Trading of Implants Segment Loss (Q1 FY27): -₹11.48 crore

What to track next

Investors should monitor the operational turnaround of the implant manufacturing segment, the effective integration of Shalby Global Technologies Pte. Ltd., and the strategic direction provided by the newly appointed Whole-Time Director.